Canaccord Genuity, a prominent financial services firm, has maintained its rating for Staar Surgical (STAA, Financial), continuing to classify the stock as a "Hold". Analyst Jon Young confirmed that there are no changes to the existing rating or price target.
The price target for STAA remains at $20.00 USD, unchanged from the prior assessment. The decision to maintain the current price target reflects the analyst's evaluation, with no percentage change reported in the target adjustment.
This update is part of the regular review process conducted by Canaccord Genuity to provide investors with the latest information and assessments regarding their portfolio options. With the rating remaining steady, investors are advised to consider this information as part of their decision-making process.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Staar Surgical Co (STAA, Financial) is $22.15 with a high estimate of $52.64 and a low estimate of $13.00. The average target implies an upside of 18.57% from the current price of $18.68. More detailed estimate data can be found on the Staar Surgical Co (STAA) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Staar Surgical Co's (STAA, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Staar Surgical Co (STAA, Financial) in one year is $39.26, suggesting a upside of 110.17% from the current price of $18.68. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Staar Surgical Co (STAA) Summary page.
